Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2022-06-08 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Application for transfer of shares admitted to trading on Euronext Growth to Oslo Børs
Regulatory Filings Classification · 95% confidence The document text is very short (326 characters) and announces an administrative action: an application by Nykode Therapeutics ASA to transfer its shares from trading on Euronext Growth to Oslo Børs. This is a specific regulatory/exchange event announcement that does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). It is a notification regarding the listing status or trading venue of the company's shares. Since there is no specific code for 'Exchange Transfer Application,' and it is a general regulatory announcement concerning the company's securities listing, the most appropriate fallback category is Regulatory Filings (RNS).
2022-06-08 English
Nykode Therapeutics ASA - Conversion to public limited liability company registered
Regulatory Filings Classification · 90% confidence The document is a short company announcement dated June 2, 2022, stating that the conversion of Nykode Therapeutics ASA into a public limited liability company has been registered following resolutions made at the Annual General Meeting (AGM) on May 12, 2022. This announcement details a change in corporate structure/status (conversion to public limited liability company) which is a significant corporate action, but it is not a standard periodic report (like 10-K or IR) or a specific transaction report (like DIRS or POS). Since it relates to a fundamental change in the company's legal status following a shareholder meeting, and it doesn't fit neatly into the other specific categories (like financing, delisting, or dividend), it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, or potentially related to capital structure changes (CAP). However, the core event is the registration of the corporate structure change following the AGM. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a non-standard, mandatory corporate status update that isn't explicitly covered by other codes like CAP (which usually implies fundraising/debt) or AGM-R (which implies meeting materials). The document length is short, suggesting it's an announcement rather than the full legal filing.
2022-06-02 English
Nykode Therapeutics ASA - Conversion to public limited liability company registered
Regulatory Filings Classification · 90% confidence The document announces a corporate action: the registration of the company's conversion to a public limited liability company, referencing a prior Annual General Meeting (AGM) resolution. This is a specific corporate governance/structural change announcement. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it relates to a fundamental change in the company's legal structure following a shareholder vote, it fits best under a general corporate announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific corporate structural updates that don't fit the other defined categories like M&A (TAR) or Share Issue (SHA). It is a formal announcement of a registered change, not a presentation (IP/AGM-R) or a management change (MANG).
2022-06-02 English
Nykode Therapeutics to Present at Jefferies Healthcare Conference
Report Publication Announcement Classification · 99% confidence The document is a brief announcement titled "Company Announcement" stating that Nykode Therapeutics will present at the Jefferies Healthcare Conference on a specific date and time, and that a webcast will be available. This is a communication intended to inform investors about an upcoming corporate event where management will discuss the company's status and outlook. This fits the description of an Investor Presentation (IP) announcement or a general corporate update, but since the core purpose is to announce participation in an investor conference where a presentation will be given, 'Investor Presentation' (IP) is the most fitting category, as it relates directly to investor engagement and presentation of company information, even if the actual presentation material isn't attached here. Given the short length and focus on announcing participation in an external investor event, it is not a full report (like 10-K or IR). It is a specific communication about an investor-facing event.
2022-06-01 English
Nykode Therapeutics to Present at Jefferies Healthcare Conference
Regulatory Filings Classification · 100% confidence The document is a short press release announcing that Nykode Therapeutics executives will present and be available for 1:1 meetings at the '2022 Jefferies Healthcare Conference' on a specific date. This type of announcement, which details participation in an external investor event (like a conference presentation), is typically classified as an Investor Presentation (IP) or, if it's purely an announcement about the event rather than the presentation material itself, it falls under general investor relations communication. Given the context of presenting corporate updates at a major industry conference, 'Investor Presentation (IP)' is the most fitting category, as these announcements precede or accompany the presentation materials intended for investors. However, since the document itself is just the announcement of the event and not the presentation slides or the full transcript, and it is very short (3295 chars), it could also be considered a Report Publication Announcement (RPA) if it were announcing the release of a formal report. Since it is announcing participation in a conference, which is a form of investor outreach, IP is stronger than RPA. If IP were not available, RNS would be the fallback. Given the options, IP best describes the nature of the communication (presenting corporate updates at a conference).
2022-06-01 English
Mandatory notification of acquisition of shares by primary insider
Director's Dealing Classification · 100% confidence The document text details a transaction involving shares of Nykode Therapeutics AS by a person discharging managerial responsibilities (Martin Nicklasson, Chair of the Board). Specifically, it reports the 'Acquisition of shares' by an insider, including the date, price, and volume. This structure perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by company directors and executives.
2022-05-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.